Clinic Roundup

• Tau Therapeutics LLC, of Charlottesville, Va., said the FDA accepted its investigational new drug application for T-type calcium channel blocker mibefradil, and the firm anticipates launching a Phase I trial in healthy volunteers March 2. Mibefradil is a compound that has been used in hypertension before Tau repositioned it for oncology indications.